| 1 | Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer显示文摘MicroRNAs (miRNAs ) 玩在在各种各样的癌症的发展和前进的关键角色。不正常的 miR-9 表示仍然保持模糊,并且卵巢的癌症的变形前进上的一致都没被到达。在这研究,从生物信息学分析的结果证明 E-cadherin mRNA 的 3-UTR 被 miR-9 直接调整。酶记者试金结果证实 miR-9 能直接指向这 3-UTR。在卵巢的癌症织物的 miR-9 和 E-cadherin 表示被 qRT-PCR 确定。移植和侵略被在 SKOV3 和 A2780 愈合弯屈和 Transwell 系统试金检测。qRT-PCR 和西方的污点被执行检测上皮 ? 间充质的联系转变的 mRNA 和蛋白质。Immunofluorescence 技术被用来分析表示和 E-cadherin, N-cadherin,和 vimentin 的 subcellular 本地化。结果证明 miR-9 经常与配对的主要的相比是在变形浆液的卵巢的癌症织物的 upregulated。miR-9 的 Upregulation 能 downregulate E-cadherin 的表示但是 upregulate 间充质的标记(N-cadherin 和 vimentin ) 的表示。miR-9 的 Overexpression 能在卵巢的癌症支持房间移植和侵略,并且这些进程能有效地经由 miR-9 禁止者被禁止。因此,我们的学习证明 miR-9 可以经由指向 E-cadherin 和一条新奇潜在的治疗学的途径控制卵巢的癌症的转移支持卵巢的癌症转移。 | Bo Zhou Hongbin Xu Meng Xia Chaoyang Sun Na Li Ensong Guo Lili Guo Wanying Shan Hao Lu Yifan Wu Yuan Li Degui Yang Danhui Weng Li Meng Junbo Hu Ding Ma Gang Chen Kezhen Li | 2017 | Frontiers of Medicine2017，11，2： | 10 |
| 2 | Serum semaphorin 4C as a diagnostic biomarker in breast cancer:A multicenter retrospective study显示文摘Background:To date,there is no approved blood-based biomarker for breast cancer detection.Herein,we aimed to assess semaphorin 4C(SEMA4C),a pivotal protein involved in breast cancer progression,as a serum diagnostic biomarker.Methods:We included 6,213 consecutive inpatients from Tongji Hospital,Qilu Hospital,and Hubei Cancer Hospital.Training cohort and two validation cohorts were introduced for diagnostic exploration and validation.A pan-cancer cohort was used to independently explore the diagnostic potential of SEMA4C among solid tumors.Breast cancer patients who underwent mass excision prior to modified radical mastectomy were also analyzed.We hypothesized that increased pretreatment serum SEMA4C levels,measured using optimized in-house enzymelinked immunosorbent assay kits,could detect breast cancer.The endpoints were diagnostic performance,including area under the receiver operating characteristic curve(AUC),sensitivity,and specificity.Post-surgery pathological diagnosis was the reference standard and breast cancer staging followed the TNM classification.There was no restriction on disease stage for eligibilities.Results:We included 2667 inpatients with breast lesions,2378 patients with other solid tumors,and 1168 healthy participants.Specifically,118 patients with breast cancer were diagnosed with stage 0(5.71%),620 with stage I(30.00%),966 with stage II(46.73%),217 with stage III(10.50%),and 8 with stage IV(0.39%).Patients with breast cancer had significantly higher serum SEMA4C levels than benign breast tumor patients and normal controls(P<0.001).Elevated serum SEMA4C levels had AUC of 0.920(95%confidence interval[CI]:0.900–0.941)and 0.932(95%CI:0.911–0.953)for breast cancer detection in the two validation cohorts.The AUCs for detecting early-stage breast cancer(n=366)and ductal carcinoma in situ(n=85)were 0.931(95%CI:0.916–0.946)and 0.879(95%CI:0.832–0.925),respectively.Serum SEMA4C levels significantly decreased after surgery,and the reduction was more striking after modified radical mastectomy,compared with mass excision(P<0.001).The positive rate of enhanced serum SEMA4C levels was 84.77%for breast cancer and below 20.75%for the other 14 solid tumors.Conclusions:Serum SEMA4C demonstrated promising potential as a candidate biomarker for breast cancer diagnosis.However,validation in prospective settings and by other study groups is warranted. | Ya Wang Long Qiao Jie Yang Xiong Li Yaqi Duan Jiahao Liu Shaoqi Chen Huayi Li Dan Liu Tian Fang Jingjing Ma Xiaoting Li Fei Ye Junxiang Wan Juncheng Wei Qin Xu Ensong Guo Ping Jin Mingfu Wu Lin Zhang Yun Xia Yaqun Wu Jun Shao Yaojun Feng Qing Zhang Zongyuan Yang Gang Chen Qinghua Zhang Xingrui Li Shixuan Wang Junbo Hu Xiaoyun Wang Mona P.Tan Kazuaki Takabe Beihua Kong Qifeng Yang Ding Ma Qinglei Gao | 2021 | Cancer Communications2021，41，12： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员